TSE:PHRM Stock Latest News
Company AnnouncementsPharmaTher Targets New U.S. Peptide Pathway With 3D-Printed Colon-Directed KPV and BPC-1573d ago
Company AnnouncementsPharmaTher Seeks FDA Special Designations for 3D-Printed Creatine in Rare Pediatric GAMT Disorder4d ago
Company AnnouncementsPharmaTher Secures Exclusive North American Rights to Craft Health’s 3D Pharma Printing Platform1M ago
Company AnnouncementsPharmaTher Taps PD Labs as U.S. Hub for 3D-Printed Personalized Medicines2M ago
Company AnnouncementsPharmaTher Unveils PERSONALIZ3D Platform to Merge Telehealth and 3D-Printed Personalized Medicines2M ago
Company AnnouncementsSource Rock Royalties Declares Monthly Dividend and Grants Incentive RSUs3M agoCompany AnnouncementsPharmaTher Files U.S. Patent to Bolster Peptide Microneedle Patch Platform6M ago
Company AnnouncementsPharmaTher Unveils PatchPrint 3D Microneedle Patch Platform and Commercialization Push7M ago
Company AnnouncementsPharmaTher Targets U.S. Peptide Market With Expansion of PharmaPatch Microneedle Platform8M ago
Company AnnouncementsPharmaTher Targets Early Entry Into Canada’s Emerging Generic Semaglutide Market9M ago- Company AnnouncementsPharmaTher Extends Microneedle Patch Platform to GLP-1 Obesity Market9M ago
Company AnnouncementsPharmaTher CEO Targets 2026 Asset Monetization After Ketamine ANDA Sale and FDA Win10M ago
Company AnnouncementsPharmaTher Sells Ketamine ANDA to Focus on Long-Acting Injectable Program11M agoCompany AnnouncementsPharmaTher Secures Rights to Long-Acting Ketamine Program for Neuropsychiatric Disorders11M ago
Company AnnouncementsPharmaTher Advances Phase 3 FDA Package for Ketamine in Parkinson’s Treatment1y ago- Company AnnouncementsPharmaTher Launches AI Platform to Expand Ketamine Portfolio1y ago
Company AnnouncementsPharmaTher Advances Ketamine Program for Parkinson’s Disease Dyskinesia1y ago
Company AnnouncementsPharmaTher Advances Ketamine Strategy with Strategic Asset Sale1y ago